InsiderTrades.com logo
Niranjan Kanesa-Thasan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Niranjan Kanesa-Thasan Biography and Net Worth

Insider of Icosavax

Niranjan Kanesa-thasan is the founder of Kanesa LLC, which was founded in 2017. He is currently the Chief Medical Officer at Icosavax, Inc. since 2018. He was previously the Chief Medical Officer-North America & VP at Novartis Vaccines & Diagnostics, Inc. from 2007 to 2015, and the Vice President-Clinical Research & Development at GSK Vaccines from 2015 to 2017.

Dr. Kanesa-thasan has an undergraduate degree from The Johns Hopkins University, a graduate degree from Uniformed Services University of the Health Sciences, and a doctorate degree from The Johns Hopkins University School of Medicine.

What is Niranjan Kanesa-Thasan's net worth?

The estimated net worth of Niranjan Kanesa-Thasan is at least $3.43 million as of January 4th, 2024. Kanesa-Thasan owns 223,980 shares of Icosavax stock worth more than $3,429,134 as of December 5th. This net worth estimate does not reflect any other assets that Kanesa-Thasan may own. Learn More about Niranjan Kanesa-Thasan's net worth.

How do I contact Niranjan Kanesa-Thasan?

The corporate mailing address for Kanesa-Thasan and other Icosavax executives is , , . Icosavax can also be reached via phone at 206-737-0085 and via email at [email protected]. Learn More on Niranjan Kanesa-Thasan's contact information.

Has Niranjan Kanesa-Thasan been buying or selling shares of Icosavax?

Niranjan Kanesa-Thasan has not been actively trading shares of Icosavax during the last quarter. Most recently, Niranjan Kanesa-Thasan sold 106,373 shares of the business's stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $15.70, for a transaction totalling $1,670,056.10. Following the completion of the sale, the insider now directly owns 223,980 shares of the company's stock, valued at $3,516,486. Learn More on Niranjan Kanesa-Thasan's trading history.

Who are Icosavax's active insiders?

Icosavax's insider roster includes Cassia Cearley (Insider), and Niranjan Kanesa-Thasan (Insider). Learn More on Icosavax's active insiders.

Niranjan Kanesa-Thasan Insider Trading History at Icosavax

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2024Sell106,373$15.70$1,670,056.10223,980View SEC Filing Icon  
12/20/2023Sell11,884$15.46$183,726.64223,980View SEC Filing Icon  
7/31/2023Sell3,323$8.86$29,441.78235,864View SEC Filing Icon  
See Full Table

Niranjan Kanesa-Thasan Buying and Selling Activity at Icosavax

This chart shows Niranjan Kanesa-Thasan's buying and selling at Icosavax by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Icosavax Company Overview

Icosavax logo
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.
Read More

Today's Range

Now: $15.31
Low: $15.31
High: $15.31

50 Day Range

MA: $15.32
Low: $15.31
High: $15.45

2 Week Range

Now: $15.31
Low: $4.75
High: $16.10

Volume

N/A

Average Volume

1,215,776 shs

Market Capitalization

$766.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28